This article is published by Terry Chrisomalis, who runs the Biotech Analysis Central pharmaceutical service on Seeking Alpha Marketplace. If you like what you read here and would like to subscribe to, I'm currently offering a two-week free trial period for subscribers to take advantage of. My service offers a deep-dive analysis of many pharmaceutical companies. The Biotech Analysis Central SA marketplace is $49 per month, but for those who sign up for the yearly plan will be able to take advantage of a 33. ...

Core Insights - ADP is set to release its first-quarter fiscal 2026 results on October 29, with a history of surpassing earnings estimates, averaging a surprise of 3.7% over the last four quarters [1] Revenue Expectations - The Zacks Consensus Estimate for ADP's revenue is $5.1 billion, reflecting a year-over-year growth of 6.1% [2] - Employer Services revenue is expected to be $3.4 billion, indicating a 5% increase from the previous year [2] - Professional Employer Organization (PEO) services are projected to generate $1.7 billion in revenue, suggesting a 7.3% year-over-year growth [3] Earnings Projections - Interest on funds held for clients is estimated at $294.4 million, representing a 16.3% increase from the prior year [3] - The average paid PEO worksite employees for the quarter is projected to be 759, with a 1% change in pay per control anticipated [4] - Earnings per share (EPS) is estimated at $2.44, indicating a year-over-year growth of 4.7% [4] Earnings Prediction Model - The current model does not predict a definitive earnings beat for ADP, with an Earnings ESP of +1.80% and a Zacks Rank of 4 (Sell) [5] Comparison with Other Companies - Western Digital is expected to report revenues of $2.7 billion, a 34% year-over-year decline, with an EPS consensus of $1.58, reflecting an 11.2% decrease [7] - Seagate Technology anticipates revenues of $2.5 billion, indicating a 16.7% year-over-year increase, with an EPS consensus of $2.36, suggesting a 49.4% growth [10]

Core Insights - The article discusses Inhibrx Biosciences, Inc. (NASDAQ: INBX) and its recent developments, particularly following the sale of INBRX-101 to Sanofi [2]. Company Overview - Inhibrx Biosciences is highlighted for its continued advancement in the biotech sector, indicating a positive trajectory despite the sale of a key asset [2]. Investment Analysis - The author operates a service called Biotech Analysis Central, which provides in-depth analysis of various pharmaceutical companies, including a model portfolio of small and mid-cap stocks [2].

Core Insights - IBM's third-quarter earnings report showed strong revenue and profit growth, yet the stock fell over 6% post-release due to market focus on a single metric [3][4][7] - The decline was primarily attributed to a slowdown in revenue growth for Red Hat, a key component of IBM's hybrid cloud strategy, which decelerated to 12% from 14% [6][8] - Despite the short-term market reaction, IBM's strategic partnership with Groq in AI technology presents a significant long-term opportunity [9][12][16] Financial Performance - Revenue reached $16.3 billion, a 9% year-over-year increase, surpassing consensus estimates [7] - Adjusted earnings per share (EPS) were $2.65, exceeding the analyst forecast of $2.44 [7] - Non-GAAP gross profit margin expanded by 1.2 percentage points to 58.7%, indicating improved profitability [7] - Management raised its full-year guidance, projecting over 5% revenue growth and approximately $14 billion in free cash flow [7][16] Strategic Developments - IBM announced a partnership with Groq, focusing on AI chip technology to enhance its enterprise AI offerings [9][10] - The collaboration aims to integrate Groq's Language Processing Units (LPUs) with IBM's Red Hat technology, enhancing speed and cost-efficiency in AI inference [12][13] - This strategic move positions IBM to address key challenges in deploying AI at scale, targeting high-value enterprise applications [11][14] Market Outlook - The market's reaction to IBM's earnings report may have created a valuation gap, as the sell-off was driven by a short-term concern rather than the company's long-term strategic initiatives [15][16] - Analysts have a 12-month stock price forecast of $288.00, indicating a potential downside of 6.60% from the current price [15] - The partnership with Groq is seen as a forward-looking strategy to capture the next wave of enterprise AI adoption, emphasizing speed and cost-efficiency [16]

Group 1 - Advanced Micro Devices (AMD) shares increased by 7% on Friday, driven by positive sentiment in the semiconductor sector [1] - The surge in AMD's stock was supported by a series of strong earnings reports and industry developments that bolstered investor confidence [1]

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh. ...

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh. ...

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh. ...

The advertisement, which features a recording of Ronald Reagan, was sharply criticized by the U.S. president. ...

Key Takeaways Carrier Global expects Q3 adjusted EPS of $0.80 and sales near $6B with mid-single-digit organic growth. Strong HVAC demand, aftermarket gains, and Viessmann integration likely boosted CARR's Q3 revenues. Weak Americas and China residential demand and European mix might have pressured CARR's quarterly margins. Carrier Global (CARR) is scheduled to report third-quarter 2025 results on Oct. 28.Carrier Global anticipates adjusted EPS to be approximately $0.80 in the quarter, with sales of about $ ...